Outlier is tracking Eli Lilly's stock performance and fundamentals as Zepbound and Mounjaro products are set to receive Medicare coverage soon.
2 reports, 2 independent
Updated Jul 10
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Outlier is tracking Eli Lilly's stock performance and fundamentals as Zepbound and Mounjaro products are set to receive Medicare coverage soon.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Medicare coverage for Eli Lilly's GLP-1 drugs has expanded.1 source
Outlier tracks Eli Lilly's stock performance and fundamentals regarding imminent Medicare coverage for Zepbound and Mounjaro.1 source
Keep exploring
The entities involved
-
Outlier
subsidiary of Scale AI
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Eli Lilly's Tirzepatide is driving 65% of the company's revenue amid intense competition in the GLP-1 market.
- The Food and Drug Administration approved Mounjaro, a drug developed by Eli Lilly and Company.
- Eli Lilly is seeking FDA approval for Zepbound and Mounjaro, tied to a $4 billion production site expansion in Kenosha, Wisconsin.